1. Aerosolization of Second-generation Triazoles: In Vitro Evaluation and Application in Therapy of Invasive Airway Aspergillosis
- Author
-
Carlo J. Iasella, Shahid Hussain, Christopher R. Ensor, Harisudhan Thanukrishnan, Joseph A. Nero, M. Hong Nguyen, Matthew R. Morrell, Raman Venkataramanan, Timothy E. Corcoran, John F. McDyer, and Cody A. Moore
- Subjects
Adult ,medicine.medical_specialty ,Posaconazole ,Antifungal Agents ,030230 surgery ,Aspergillosis ,Gastroenterology ,03 medical and health sciences ,chemistry.chemical_compound ,Galactomannan ,0302 clinical medicine ,Internal medicine ,Administration, Inhalation ,Bronchoscopy ,medicine ,Humans ,Respiratory Tract Infections ,Aerosolization ,Voriconazole ,Aerosols ,Transplantation ,medicine.diagnostic_test ,business.industry ,Triazoles ,medicine.disease ,Regimen ,Bronchoalveolar lavage ,chemistry ,Feasibility Studies ,030211 gastroenterology & hepatology ,Female ,Caspofungin ,business ,Invasive Fungal Infections ,medicine.drug ,Lung Transplantation - Abstract
BACKGROUND A lung transplant patient with invasive aspergillosis (IA) manifested symptoms of voriconazole-induced transaminitis with systemic voriconazole and progression of IA after switching to oral posaconazole. With limited options for standard triazole therapy, aerosolized delivery with one of the second-generation triazoles was considered. METHODS Feasibility for aerosolized delivery was evaluated using cascade impactor and analysis of physicochemical characteristics of voriconazole (10 mg/mL) and posaconazole (6, 12 mg/mL) solutions. RESULTS Both triazoles showed favorable characteristics for aerosol delivery with mass median aerodynamic diameter, geometric standard deviation, respirable fraction (
- Published
- 2019